Daiichi Sankyo Unit Says Rival Infringed IP As Trial Opens

By Dorothy Atkins (July 12, 2021, 9:35 PM EDT) -- Counsel for a Daiichi Sankyo subsidiary told a California federal jury during trial openings on Monday that Novartis owes royalties for selling drugs that allegedly infringe its billion-dollar skin cancer treatment patents, while Novartis' attorney countered that his client should pay nothing because the patents are invalid.

During the first day of trial in Oakland, California, Plexxikon's counsel, Daralyn Durie of Durie Tangri LLP, told an eight-member jury that Novartis' drug Tafinlar infringes Plexxikon's two patents that cover compounds that use the same mechanism of action in its rival cancer treatment drug Zelboraf.

Durie said Plexxikon's patented cell technology works like...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!